Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will develop and commercialize the biosimilar form of Enbrel - HD203 - in all markets except Korea and Turkey, where Hanwha retained marketing rights.